AstraZeneca Resumes Its COVID-19 Vaccine Trials In The U.K.

AstraZeneca Resumes Its COVID-19 Vaccine Trials In The U.K.

Pharmaceutical company AstraZeneca Plc has announced that it has suspended global trials of its experimental COVID-19 vaccine, including late-stage trials, due to illness in one of the participants.

Earlier on September 6, the standard review process triggered a voluntary pause to vaccination across all global trials to allow the review of safety data by independent committees and worldwide regulators.

While AstraZeneca resumes clinical trials in the United Kingdom, the Indian regulator has asked Serum Institute of India (SII) to suspend recruitments for phase-2 and 3 clinical trials of the Oxford-AstraZeneca vaccine candidate and has directed the firm to increase the safety monitoring of the subjects already vaccinated as part of the trial.

The nature of the disease has not been disclosed, but the trial participant is expected to recover, according to Stat News, which was the first to report the suspension of trials.

AstraZeneca previously also received permission to conduct the third stage of clinical trials of the AZD1222 vaccine in Russian Federation, follows from the state register of clinical trials.

The Medicines Health Regulatory Authority (MHRA) has said it is now safe to continue the trial. It had begun a large phase 3 trial in the U.S.at the end of August, with the aim of enrolling 30,000 people. Governor Joao Doria said phase two trials had shown that the vaccine produced an immune response in 98 percent of recipients over 60 years old, with no adverse side effects reported so far.

China criticises Australia for raiding Chinese journalists’ homes
The questioning was conducted in relation to the case of Cheng Lei, an Australian journalist now detained in China. The Australian Foreign Office and Security Intelligence Organization (ASIO) have not commented on the issue.

The Federal University of Sao Paulo, which is conducting the paused trials, said in a statement that 4,600 of the planned 5,000 volunteers have been recruited and vaccinated without any of them reporting any serious health issues.

"As part of the pilot delivery, the logistics chains for delivering the vaccine to the constituent entities of the Russian Federation, distribution and organization of vaccination against Covid-19 of citizens from the high-risk group will be ensured", the ministry's spokesperson said.

According to an article published on the University's Vaccine Development website, "Participants are being randomised to receive two doses of either ChAdOx1 nCoV-19 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine than the saline control". The MHRA, in turn, confirmed that the trials could resume, the Swedish-British drug giant added.

Talking about the development, UK's Secretary of State for Health Matt Hancock wrote on Twitter, "Good news for everyone the Oxford vaccine trials are back up and running".

The United States Centers for Disease Control and Prevention notified all 50 states on August 27 to get ready to distribute two COVID-19 vaccines starting late October.

Related Articles